SPRC - SciSparc Ltd. Stock Price and Quote

SPRC [NASD]

Index	-	P/E	-	EPS (ttm)	-3.05	Insider Own	6.47%	Shs Outstand	3.53M	Perf Week	-13.46%
Market Cap	1.59M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	3.30M	Perf Month	-39.02%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.84%	Short Float / Ratio	3.54% / 0.11	Perf Quarter	-38.45%
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Interest	0.12M	Perf Half Y	-41.59%
Book/sh	0.86	P/B	0.52	EPS next Y	-	ROA	-	Target Price	-	Perf Year	-88.40%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-	52W Range	0.47 - 5.00	Perf YTD	-40.44%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-91.00%	Beta	-
Dividend %	-	Quick Ratio	-	Sales past 5Y	-	Gross Margin	-	52W Low	-4.26%	ATR	0.06
Employees	3	Current Ratio	-	Sales Q/Q	-	Oper. Margin	-	RSI (14)	23.65	Volatility	8.56% 9.28%
Optionable	No	Debt/Eq	-	EPS Q/Q	-	Profit Margin	-	Rel Volume	0.06	Prev Close	0.48
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	1.06M	Price	0.45
Recom	-	SMA20	-24.71%	SMA50	-41.75%	SMA200	-57.67%	Volume	63,667	Change	-6.25%

Mar-28-23 09:00AM	SciSparc completes the sale of a 49% interest in its Subsidiary that owns Wellution for $3 million GlobeNewswire -5.35%
Mar-10-23 04:15PM	SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification GlobeNewswire
Mar-09-23 07:30AM	SciSparc Receives Approval to conduct its Phase IIb Clinical Trial for SCI-110 to treat Tourette Syndrome GlobeNewswire
Mar-06-23 07:45AM	SciSparc Successfully Completed Production of its Proprietary Drug Candidate SCI-110 for its Upcoming Clinical Trial On Tourette Syndrome GlobeNewswire
Feb-27-23 09:11AM	SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder GlobeNewswire -11.64%
08:45AM	Loading…
Feb-23-23 08:45AM	Jeffs' Brands Entered into a Definitive Agreement to Acquire a 49% interest in a company that Owns Wellution, a Top Seller Brand on Amazon for $2.5 million GlobeNewswire
08:30AM	SciSparc Signs a Definitive Agreement to Sell 49% interest in its Subsidiary that Owns Wellution for $2.5 million GlobeNewswire
Feb-22-23 08:00AM	SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds GlobeNewswire +6.64%
08:00AM	Israel-Based Clearmind Medicine Files Patent Applications for Three Unique Combinations of Future Psychedelic-Based Compounds GlobeNewswire
Feb-17-23 08:00AM	SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Reached First Milestone for its Future Machine Learning System GlobeNewswire +9.89%
Feb-15-23 08:30AM	SciSparc and Clearmind Collaboration Strengthens IP Portfolio with Three Provisional Patent Applications in the US GlobeNewswire
08:30AM	Israel-Based Clearmind Medicine Strengthening IP Portfolio with Three Provisional Patent Applications in the US GlobeNewswire
Jan-25-23 08:30AM	SciSparc Announces Corporate Restructuring plan GlobeNewswire -5.15%
Jan-23-23 02:15PM	Small-Cap Companies Allege Illegal Short Selling The Wall Street Journal +17.16%
09:20AM	SciSparc to Investigate and Evaluate Concerns of Illegal Trading of its Ordinary Shares GlobeNewswire
07:30AM	Loading…
Jan-18-23 07:30AM	SciSparc Receives Approval to Conduct its Clinical Trial in Children with Autism Spectrum Disorder at the Soroka Medical Center GlobeNewswire
Jan-17-23 08:30AM	SciSparc Announces Additional Positive Results from the Third Part of Clearmind Medicine Inc. Pre-Clinical Study for Cocaine Addiction Treatment GlobeNewswire +7.00%
Jan-09-23 08:30AM	SciSparc Signs Agreement to Conduct its Clinical Trial in Autism Spectrum Disorder with Soroka Medical Center GlobeNewswire
Jan-05-23 09:00AM	SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial GlobeNewswire +12.88%
Dec-14-22 09:15AM	SciSparc Enters Into Non-Binding Letter of Intent to Sell a 50% interest in its Subsidiary that Owns an Amazon Top Seller Brand GlobeNewswire -9.29%
Dec-07-22 08:40AM	SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy GlobeNewswire -7.41%
Nov-29-22 08:00AM	SciSparc Regains Compliance with Nasdaq Minimum Closing Bid Price Rule GlobeNewswire
Nov-15-22 10:25AM	Can This Companys Positive Results For Psychedelic Combination Treatment Provide Hope For Alcohol And Cocaine Addiction Problems? News Direct
09:15AM	SciSparc Enters Into Letter of Intent with an E-commerce Company to Establish a Joint Venture to Market and Develop a New Product Line GlobeNewswire
Nov-08-22 07:00AM	SciSparc Gains Competitive Edge with Additional U.S. Patent Granted GlobeNewswire
Nov-07-22 08:45AM	SciSparc Announced Positive Interim Results Meeting Primary Endpoints at Phase IIa Study in Alzheimers Disease Patients with Agitation GlobeNewswire
Nov-01-22 08:30AM	SciSparc: Wellution Signs an Agreement with Logistics Facilities in New Jersey to Supports its Expansion to Additional e-Commerce Platforms GlobeNewswire +12.09%
Oct-28-22 07:45AM	SciSparc: Wellution Successfully Launched a New Keto Gummies Apple Cider Vinegar Product and Generated $100,000 In Revenues Within 30 Days GlobeNewswire
Oct-12-22 09:00AM	SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification GlobeNewswire
Sep-30-22 07:00AM	SciSparc Completes the Acquisition of Wellution, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million GlobeNewswire +8.94%
08:30AM	Loading…
Sep-22-22 08:30AM	Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome GlobeNewswire
07:46AM	SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields 3rd Patent Application for the Treating of Obesity and Metabolic Syndromes GlobeNewswire
Sep-14-22 07:35AM	SciSparc Enters Agreement to Acquire Wellution, Top Seller of American Food Supplements and Cosmetics Brand on Amazon, for $20 million GlobeNewswire +23.89%
Aug-24-22 07:30AM	SciSparc Ltd. Announces Additional Positive Results for the Cocaine Addiction Treatment of its Psychedelic-based Pharma Collaboration with Clearmind Medicine Inc. GlobeNewswire +19.89%
Aug-19-22 06:45AM	Scisparc Announces the Full Exercise of Pre-Funded Warrants GlobeNewswire -9.48%
Aug-18-22 08:15AM	SciSparc will Deposit $1 million in Escrow for its Intention to Enter Into an Agreement to Acquire American Food Supplements and Cosmetics Brand GlobeNewswire
Aug-15-22 08:30AM	SciSparc Signs a Non- Binding Letter of Intent to Acquire American Food Supplements and Cosmetics Brand in Approximately $20 Million Deal GlobeNewswire -11.00%
Aug-12-22 08:00AM	SciSparc Issued Israeli Patent for its Core Technology for Treating Central Nervous Systems Disorders GlobeNewswire -5.88%
Aug-08-22 08:55AM	SciSparc Announces Israeli Ministry of Health Approval to Conduct its Clinical Trial in Autism Spectrum Disorder GlobeNewswire
Aug-01-22 09:30AM	SciSparc Signs Clinical Trial Agreement with Yale University to Conduct its Phase IIb Trial in Tourette Syndrome GlobeNewswire -9.49%
Jul-21-22 07:22AM	SPRC: Clinical-stage pharma company using cannabinoids to address serious health issues. Zacks Small Cap Research
Jul-08-22 08:30AM	SciSparc Announces Expanding its Clinical Operations to Include a U.S. Site Towards its Phase IIb Trial with its Proprietary SCI-110 for the Treatment of Tourette Syndrome GlobeNewswire -5.43%
Jul-07-22 08:30AM	SciSparc's JV MitoCareX Bio Launches its Advanced New Laboratory Facility GlobeNewswire -7.63%
08:00AM	Traders News Source Interviews Oz Adler Chief Executive Officer at SciSparc Ltd. ACCESSWIRE
Jul-06-22 09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? PR Newswire
08:30AM	SciSparc Board of Directors to Promote Buyback Program of up to $1 Million GlobeNewswire
Jun-29-22 08:30AM	SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome GlobeNewswire
Jun-23-22 09:30AM	SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder GlobeNewswire +7.25%
Jun-15-22 08:30AM	SciSparc Reinforces its New JV for Targeting Discovery with a Global Expert in the Field of Mitochondrial Transport Proteins GlobeNewswire
Jun-09-22 08:30AM	SciSparc's Board of Directors Provides Strategic Decision GlobeNewswire
Jun-07-22 08:30AM	SciSparc Ltd. Announces Initial Positive Results for the Cocaine Addiction Treatment of Clearmind Medicine Inc. GlobeNewswire
Jun-02-22 09:55AM	Aegis Capital Corp. Acted as Exclusive Placement Agent on a $10 Million Private Placement Priced At-the-Market for SciSparc Ltd. (NASDAQ:SPRC). ACCESSWIRE
08:30AM	SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields Another Patent Application for their Proprietary Psychedelic Combination to Treat Cocaine Addiction GlobeNewswire
Jun-01-22 04:07PM	SciSparc Ltd. Announces Closing of $10 Million Private Placement Priced At-the-Market GlobeNewswire
May-31-22 08:30AM	SciSparc to Collaborate with Polyrizon for Brain Targeting Using Intranasal Hydrogel Systems GlobeNewswire +5.31%
May-27-22 09:15AM	SciSparc Announces Pricing of $10 Million Private Placement Priced At-the-Market GlobeNewswire -13.81%
May-26-22 08:30AM	SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome GlobeNewswire +41.10%
May-24-22 08:30AM	SciSparc and Clearmind Medicine Inc. Collaboration Yields Positive Results for its Psychedelic Combination Treatment GlobeNewswire +42.86%
May-10-22 08:30AM	SciSparc Ltd. and Clearmind Medicine Inc. Collaboration Yields New Patent Application for Psychedelic Combination Treatment for Binge Behaviors GlobeNewswire
08:30AM	Clearmind Medicine Inc. and SciSparc Ltd., Collaboration Yields New Provisional Patent Application for Psychedelic Combination Treatment for Binge Behaviors GlobeNewswire
May-02-22 08:41AM	SciSparc Files Annual Report for Year Ended December 31, 2021 and Provides Corporate Update GlobeNewswire
Mar-31-22 09:30AM	SciSparc Announces Closing of New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases GlobeNewswire
Mar-30-22 08:30AM	Prof. Avi Schroeder Joins SciSparc's Scientific Advisory Board to Support the Company's Development of SCI-160 for Treating Pain GlobeNewswire +8.38%
Mar-17-22 08:00AM	SciSparc Announces Positive Results from Psychedelic-Based Pre-Clinical Trial PR Newswire
Mar-10-22 08:30AM	SciSparc Launches New JV Targeting Discovery of Potential Drugs for Cancers and Infectious Diseases PR Newswire

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. SciSparc Ltd. has collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience